Rilonacept (Arcalyst)

Arcalyst (rilonacept) is covered only for FDA‑approved cryopyrin‑associated periodic syndromes (CAPS — FCAS and MWS) in patients aged ≥12 and non‑FDA uses are excluded. Initial approval (3 months) requires prescription by or consultation with a rheumatologist, geneticist, allergist, immunologist, or dermatologist with documentation of diagnosis and age (and weight for pediatric dosing), and renewals (12 months) require documented clinical response and adherence to prescribing‑information dosing.

"Arcalyst is an interleukin-1 blocker indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrom..."

Sign up to see full coverage criteria, indications, and limitations.